This Week at Peak Human: CoQ10's Heart-Failure Number, and the Real Evidence on hCG Fertility

A note from Dr. Goel

This week's issue is our regular site digest — a look at everything new on peakhuman.ai over the past seven days. We updated the Coenzyme Q10 (Ubiquinol) page with a striking new heart-failure meta-analysis, published two connected evidence reviews on hCG and male fertility, took an honest look at what actually helps (and what's risky) during an MDMA comedown, added new mechanistic evidence to our Arterosil glycocalyx page, and refreshed the Breathwork intervention page with the latest randomized-trial data. As always: evidence first, hype never.

— Dr. Sanjeev Goel

What's new at Peak Human this week

Six updates from the past seven days — starting with the one that surprised me most.

CoQ10 (Ubiquinol): a bigger number than I expected

We updated our CoQ10 supplement page with new cardiovascular evidence. A 2024 meta-analysis of 33 randomized controlled trials (Xu et al., BMC Cardiovascular Disorders) found that adding CoQ10 to standard heart-failure therapy reduced all-cause mortality by roughly 36% (RR 0.64, 95% CI 0.48–0.85) and heart-failure hospitalizations by roughly 50% (RR 0.50, 95% CI 0.37–0.67), alongside improvements in ejection fraction and walk distance. The caveat matters: a separate 2025 NHANES cohort found no mortality benefit from CoQ10 use in the general population — the signal so far looks specific to diseased hearts, not a general longevity effect.

How effective is hCG at raising testosterone?

New evidence review. Unlike exogenous testosterone, hCG stimulates the testis directly — raising testosterone while preserving the intratesticular testosterone and fertility that TRT shuts down. We break down how large that rise actually is in the trial data, and who it's a genuine fit for.

Oligospermia: do hCG, hMG, or clomiphene actually work?

The companion piece to the article above, sorted by cause. In men with hypogonadotropic hypogonadism, gonadotropin therapy induces sperm production in roughly three-quarters of cases. In idiopathic low sperm count with normal FSH — the more common scenario — the evidence for the same drugs is far weaker, and testosterone itself is the wrong tool, since it suppresses fertility further.

What actually helps an MDMA comedown

The mid-week "Tuesday blues" some people report after MDMA use are real, and the internet is full of "rolling supplement" stacks claiming to prevent them. We reviewed the evidence behind vitamin C, alpha-lipoic acid, 5-HTP, EGCG, and magnesium — and flagged the one combination, 5-HTP taken too soon after MDMA, that carries a genuine serotonin syndrome risk. This is a harm-reduction evidence review, not an endorsement of MDMA use, which remains illegal outside supervised clinical trials in most jurisdictions.

Arterosil: rebuilding the vascular glycocalyx

We added a new evidence chart to our Arterosil page. Its active ingredient, rhamnan sulfate, cut LDL passage across cultured endothelial cells roughly 4-fold and reduced aortic plaque by about 40% in mice on a high-fat diet. Human evidence is still limited to one small, uncontrolled case series — a promising mechanism with only preliminary human data.

Breathwork: the randomized-trial evidence, finally quantified

We refreshed our Breathwork intervention page with the latest data. A 2023 meta-analysis of randomized trials found small-to-moderate reductions in stress, anxiety, and depression versus control, and a 2025 randomized trial of online guided sessions found a notably larger anxiety benefit. Simple, low-cost, and now backed by real trial data rather than just tradition.

My take: A 36% drop in mortality is a big number for a supplement most people already have in their cabinet — but it's specific to people who already have heart failure on top of standard medical therapy, not a reason for healthy adults to megadose CoQ10 for longevity. If you have heart failure, this is worth raising with your cardiologist. If you don't, the general-population data so far are unconvincing, and I wouldn't oversell it.

If any of this week's hormone or cardiovascular deep-dives raised follow-up questions, our physician-led testing and optimization programs can help you figure out what's actually worth pursuing for your own biology.

Longevity news worth your minute

Rapamycin's healthspan data stays modest in healthy adults. The PEARL trial — a 48-week randomized, placebo-controlled study of low-dose intermittent rapamycin in healthy older adults — found it was generally well tolerated but did not show the dramatic healthspan gains seen in animal studies, underscoring why off-label longevity dosing is still getting ahead of the human evidence.

⚕️ Important disclaimer

This newsletter is for educational purposes only and is not medical advice. Compounds discussed may be investigational and not FDA-approved. Nothing here is a recommendation to start, stop, or change any treatment. Peptide and metabolic therapies carry real risks and should only be used under qualified medical supervision. Always consult your physician before making health decisions.